Aurinia Pharmaceuticals (AUPH) vs Biohaven (BHVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biohaven (BHVN) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 27.9% versus a loss of 6.3%. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.87 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | BHVN |
|---|---|---|
| Share price | $14.70 | $12.39 |
| Market cap | $1.97B | $1.87B |
| 1-day change | -1.28% | -9.23% |
| YTD return | -7.84% | +9.74% |
| 1-year return | -6.25% | +27.86% |
| 5-year return | -23.95% | — |
| P/E ratio (TTM) | 6.45 | — |
| Forward P/E | 12.67 | — |
| EPS (TTM) | $2.28 | $-3.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | — |
| Revenue growth (YoY) | +20.38% | — |
| Net income (latest FY) | $287.20M | $-738.82M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | — |
| Net margin | 101.47% | — |
| 52-week high | $19.25 | $18.24 |
| 52-week low | $13.52 | $8.03 |
| Distance from 52-week high | -23.64% | -32.07% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +25.85% | +102.82% |
| Average volume | 858.74K | 3.24M |
| Shares outstanding | 134.00M | 151.06M |
| Employees | 128 | 274 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed AUPH by 34.1 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
AUPH vs BHVN FAQ
Which is bigger, Aurinia Pharmaceuticals or Biohaven?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.87B for Biohaven (BHVN).
Which stock has performed better over the past year, AUPH or BHVN?
BHVN returned +27.86% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Biohaven in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.